Navigation Links
Mayo Clinic: Rotavirus vaccine given to newborns in Africa is effective
Date:6/17/2013

ROCHESTER, Minn. -- Mayo Clinic and other researchers have shown that a vaccine given to newborns is at least 60 percent effective against rotavirus in Ghana. Rotavirus causes fever, vomiting and diarrhea, which in infants can cause severe dehydration. In developed nations, the condition often results in an emergency room visit or an occasional hospitalization, but is rarely fatal. In developing countries, however, rotavirus-related illness causes approximately 500,000 deaths per year. The findings appear this week in the Journal of Infectious Diseases.

Currently, there is no neonatal rotavirus vaccine available and infants do not receive their first dose of a rotavirus vaccine until they are approximately 2 months old, leaving younger infants at serious risk of rotavirus infection. In the study, the first of two doses was administered within the first 29 days of life (neonatal dosing), and the second dose before 60 days of age.

"For the first time in a large-scale study, we have demonstrated that protection against rotavirus gastroenteritis can be achieved earlier in life," says co-author and pediatrician Robert M. Jacobson, M.D., of the Mayo Clinic Children's Center. "The next step should be additional studies in neonates to provide earlier protection against life-threatening rotavirus diarrhea. The rotavirus vaccines used in America and Europe are administered later -- when babies are 2 to 4 months old -- but younger infants also contract the virus in the first two months of life."

Two vaccines serve as standard protection in developed countries, but are not especially effective in African or Asian countries, says Dr. Jacobson. Besides, he says, protection is also needed from birth due to the widespread risk of the virus.

"There is a huge protection gap right now in the first months of life," says Dr. Jacobson. "This study points to a clear and practical solution."

In Ghana, 998 newborns were selected for the randomized, double-blind, placebo trial from two of the poorest parts of the country. Half received the oral reassortant rotavirus tetravalent vaccine (RRV-TV) in the first two months of life, half received a placebo. Results showed a significant response in parameters of efficacy, safety and immune impact of the vaccine.


'/>"/>

Contact: Bob Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Mayo Clinic: How gold nanoparticles can help fight ovarian cancer
2. Mayo Clinic: Inflammatory bowel disease raises risk of melanoma
3. Mayo Clinic: Scheduled imaging studies provide little help detecting relapse of aggressive lymphoma
4. Mayo Clinic: New multiple myeloma treatment guidelines personalize therapy for patients
5. Mayo Clinic: Skin problems, joint disorders top list of reasons people visit doctors
6. Mayo Clinic: 2-drug combination may slow deadly thyroid cancer
7. Mayo Clinic: Less invasive surgery detects residual breast cancer in lymph nodes after chemotherapy
8. Mayo Clinic: Antidepressant eases radiation-related mouth pain in head, neck cancer
9. Mayo Clinic: Diabetes can be controlled in patients after pancreas removal
10. Mayo Clinic: Drug duo turns on cancer-fighting gene in kidney, breast cancers
11. Mayo Clinic: Common blood pressure drug linked to severe GI problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2020)... ... 2020 , ... National Association of Chain Drug Stores (NACDS) ... nation’s ongoing preparations for the eventual deployment of COVID-19 vaccines: , “By any ... essential component of vaccine deployment. They will need to be part of the ...
(Date:7/22/2020)... ... 2020 , ... As part of August’s Children’s Eye Health and Safety Month, and as a ... at Prevent Blindness (NCCVEH) has released an updated version of the report titled ... goal of the report is , to provide updated surveillance ...
(Date:7/22/2020)... , ... July 22, 2020 , ... ... unique opioid related compositions of matter and manufacturing processes from Brock University for ... auction lot 114 , sold by Brock University provides the manufacturing processes of ...
(Date:7/22/2020)... ... July 22, 2020 , ... Healthcare data curation ... Data Curation as a Service (DCaaS) solution for payers, providers, healthcare systems, and ... data curation parameters and are custom tailored to provide clients a clear, trusted, ...
(Date:7/18/2020)... (PRWEB) , ... July 17, 2020 , ... ... an Honorable Mention in the Hermes Creative Awards, was a charitable push put ... spread positivity to contrast the news during the pandemic, HMI asked individuals in ...
Breaking Medicine News(10 mins):
(Date:7/31/2020)... ... July 31, 2020 , ... In an informal poll of ... majority voted for a refreshed Minnesota Twins “Minnie and Paul” logo that is more ... circa 1960. That was well before the civil rights movement in the United States. ...
(Date:7/22/2020)... Pa. (PRWEB) , ... July 22, 2020 , ... ... agency for the nation’s top healthcare companies and part of WPP (NYSE:WPP), has ... Warren, EVP, Media Investment. , As the agency ventures further into healthcare consumer ...
(Date:7/10/2020)... ... July 10, 2020 , ... ... and advanced manufacturing solutions provider today announced that their CANSWAB™ nasopharyngeal swabs are ... Company has engineered a new 3D-printed swab design and has trademarked the name ...
Breaking Medicine Technology: